NPM1-mutant myeloid neoplasms should be treated with AML-type Rx irrespective of blast percentage. With intensive chemo, maybe no need for SCT. MD Anderson Cancer Center ACS Journal Cancer doi.org/10.1002/cncr.3… #leusm #AML

Wow ! Thank you for sharing this. Another area where MDS diagnosis needs improvement would be the quantification of burden of disease. The enumeration of blast count in itself is a poor marker of clinical behaviour. Maybe we can develop a flow marker of " % dysplastic cells"

Congratulations Ivan Pasic Tommy Alfaro Moya . Great work of getting this out !

Wow! This is such an apt analogy. For transplant consults we used to give analogy of destroying the weed in your garden and borrowing some seeds from your neighbours garden to replant your own!!

Real talk about chronic #GVHD. A🧵: Clear representation of BMT CTN 1703 data is necessary for individuals to make informed decisions as to whether #PTCy has transformed the landscape of chronic #GVHD vs the prior standard. See 👀: Chronic graft-versus-host disease:

I’m officially a Lymphoma/ASCT doctor after I accomplished my fellowship at Princess Margaret Hospital.🇨🇦 I’m back in Mexico City, looking forward to collaborating in clinical research apply the knowledge to our resource-limiting setting. 💪🏼🇲🇽 #lym

The addition of blinatumomab to consolidation chemotherapy in adults with B-cell precursor acute lymphoblastic leukemia who had minimal residual disease–negative status after treatment improved overall and relapse-free survival. Full trial results: nej.md/4deohvj

All the best for your future endeavours Juan !

👉👉👉Delighted to share review article on #CLL (with my colleagues Drs Bill Wierda and Susan O’Brien) published in the Journal Lancet today!! The Lancet Bill Wierda, MD, PhD MD Anderson Cancer Center Hagop Kantarjian,MD Chronic lymphocytic leukaemia - The Lancet thelancet.com/journals/lance…

Wow, love the discussion this question generated! There is never a single side to most decisions in medicine!

Significant progress in #CLL therapy over the last decade as highlighted in this review article in The Lancet by Nitin Jain Bill Wierda, MD, PhD Susan O’Brien doi.org/10.1016/S0140-… MD Anderson Cancer Center #Leukemia #leusm

Felicidades!!

As transplanters, our goal remains to help patients return to normal, in every sense. Patients & their families show extraordinary resilience & determination to endure their #BMT journey. #bmtsm We are proud to celebrate their successes at our #BMTSurvivorshipDay2024

ASTCT applauds the U.S. FDA approval of Niktimvo (axatilimab-csfr), a significant new therapy for patients suffering from cGVHD. ASTCT President Corey Cutler served as co-first author on the supporting AGAVE-201 study. Read the full press release: ow.ly/lZVr50SY42j

🚨 🚨 🚨 Massive NPM1m AML dataset from Blood Journal out today with some possibly practice changing findings….. AML Hub Aaron Goodman - “Papa Heme” Joshua Fein Sanjay Patel, MD ashpublications.org/blood/article/… 1/

Dr John Seymour giving Dr Michael Keating plenary award lecture at #SOHO24 Society of Hematologic Oncology (SOHO) First patient ever treated with venetoclax (previously called ABT-199) was in June 2011 in Australia with Dr Seymour. Amazing how this drug has changed the practice of leukemia care,

"Exciting to see the expanding indications of flow cytometry in myeloma! Congrats, Sreejesh!"

More than 400 survivors, donors, healthcare providers, family members and supporters of University Health Network's Princess Margaret Cancer Centre celebrated Allogeneic Blood & Bone Marrow Transplant Patient Survivorship Day at Black Creek Pioneer Village 💚

👉👉 I am excited to welcome you to the 2024 Summit on Hematological Cancers on October 11th - 13th! I hope you’ll join me for this exciting event in beautiful Nashville, TN! I will be Co-Chairing the meeting with my Co-Chairs Navneet Majhail, MD, MS Soni Smith MD Shaji Kumar Register